subscribe: Posts | Comments

Professional concern for quality of cervical cancer vaccine

0 comments

Summary of BBC Health News 13.2.11

The British Association for Sexual Health and HIV (BASHH) have questioned 520 sexual health professionals following a concern that the NHS cervical cancer vaccine (Cervarix) does not protect against genital warts.

The results have shown that 9 out of 10 specialists would pay for the private vaccine over the NHS one.

Both cervical cancer and genital warts stem from the human papillomavirus (HPV), although it should be noted that in the majority of cases, the presence of HPV is relatively symptom free, causing warts and little else.

As a result of an increase in awareness about cervical cancer, the government launched a vaccination programme in 2008, offering Cervarix to schoogirls aged 12-14.

Gardasil, the vaccine for cervical cancer which is available privately, protects against genital warts and is 90% effective at protecting against warts on the vocal cords.

However, with rising levels of women aged 16 to 19 being diagnosed with genital warts, 93% specialists are opting to pay for private vaccinations for their daughters and advising friends to do the same.

Unsuprisingly the Department of Health are more concerned about cost than health and they argue that Cervarix provides ‘cost-effective’ care, and has the ‘best overall value’.

On initiation of the vaccination programme, the government contract to Cervarix was for three years. It is under review in April.

It is easy to criticise the Department of Health for their actions (or lack of them), but the criticism needs be directed to its relationship with the pharmaceutical industry as well.

Throughout all the NHS reforms, there will necessarily be struggles between pharmaceuticals, cost, quality and care. This story shows only the very tip of concern.

Leave a Reply

Your email address will not be published. Required fields are marked *